FLNA · Filana Therapeutics, Inc. · Financials
Market Cap
$37.32M
Shares
48.31M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$41.12M
+277.6%
FY2013
Net Income
-$90.97M
-273.7%
FY2025
Operating Margin
76.28%
+112.1pp
FY2013
Diluted EPS
-$1.88
-28.8%
FY2025
Operating Cash Flow
-$32.25M
+72.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — | — | — | — | — | $41.12M | $10.89M | $11.48M | $16.81M | $20.56M | |
| $17.47M | $26.59M | $69.64M | $89.42M | $68.03M | $24.81M | — | — | $2.97M | $7.62M | $9.18M | $9.1M | $7.31M | $4.92M | $7.61M | $8.3M | $15.75M | $21.06M | |
| $64.5M | $68.8M | $71.81M | $16.53M | $11.99M | $8.06M | $3.74M | $3.39M | $3.69M | $4.33M | $5.78M | $5.1M | $5.13M | $4.84M | $7.18M | $6.7M | $14.77M | $6.26M | |
| — | $33K | $180K | $446K | $497K | $224K | $0 | — | — | — | — | — | — | — | — | — | — | — | |
| $11K | — | — | — | — | — | $22K | $58K | $69K | $68K | $58K | $45K | $15K | — | $122K | $163K | $232K | $257K | |
| $81.97M | $95.39M | $141.45M | $105.96M | $80.02M | $32.87M | $6.45M | $4.96M | $6.66M | $11.95M | $14.96M | $14.2M | $12.43M | $9.75M | $14.79M | $15M | $30.51M | $27.32M | |
| -$81.97M | -$95.39M | -$141.45M | -$105.96M | -$80.02M | -$32.87M | -$6.45M | -$4.96M | -$6.66M | -$11.95M | -$14.96M | -$14.2M | -$12.43M | $31.37M | -$3.9M | -$3.51M | -$13.7M | -$6.75M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 76.28% | -35.79% | -30.6% | -81.52% | -32.85% | |
| -$12.72M | — | — | — | — | — | -$6.42M | -$4.9M | -$6.59M | -$11.88M | -$14.9M | -$14.16M | -$12.42M | — | -$3.78M | -$3.35M | -$13.47M | -$6.5M | |
| -$73K | -$203K | $411K | $907K | $997K | $434K | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$14.15M | -$12.39M | $31.47M | -$3.45M | -$2.61M | -$12.02M | -$4.98M | |
| $0 | $0 | $0 | — | — | — | — | — | — | — | — | — | — | -$73K | $0 | $0 | — | -$1.51M | |
| -$77.9M | -$90.97M | -$24.34M | -$97.22M | -$76.25M | -$32.39M | -$6.33M | -$4.63M | -$6.56M | -$11.91M | -$14.85M | -$14.15M | -$12.39M | $31.54M | -$3.45M | -$2.61M | -$12.02M | -$3.47M | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | 76.71% | -31.64% | -22.75% | -71.53% | -16.86% | |
| -$9.62M | — | — | — | — | — | — | — | — | -$11.91M | -$14.85M | -$14.15M | -$12.39M | $31.54M | -$3.57M | -$3.01M | -$11.85M | -$3.45M | |
| USD/shares | -$1.61 | -$1.88 | -$0.53 | -$2.32 | -$1.90 | -$0.82 | — | — | — | — | — | -$0.31 | -$0.27 | $0.70 | -$0.08 | -$0.06 | — | — |
| USD/shares | — | -$1.88 | -$1.46 | -$2.32 | -$1.90 | — | — | — | — | — | — | -$0.31 | -$0.27 | $0.70 | -$0.08 | -$0.06 | — | — |
| shares | — | 48.3M | 46.33M | 41.93M | 40.2M | 39.41M | 26.11M | 17.41M | 10.68M | 6.54M | 6.52M | 45.76M | 45.27M | 45.01M | 44.75M | 44.16M | 42.64K | — |
| shares | — | 48.3M | 46.6M | 41.93M | 40.2M | 39.41M | 26.11M | 17.41M | 10.68M | 6.54M | 6.52M | 45.76M | 45.27M | 45.21M | 44.75M | 44.16M | 42.64K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Debt data is being processed. Please check back later.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 5.48×
EV/EBIT
—
P/E (TTM)
—
Peer median 3.70×
Peer medians compare against the 274 similar-size Biotechnology companies (of 536 listed).
Key facts
CIK
1069530
CUSIP
14817C107
13F (30d)
23 filings
23 filers
Visit website
Investor relations